Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond)

VA Office of Research and Development2 sites in 1 country44 target enrollmentOctober 1, 2020

ConditionsChronic Pain

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Pain
Sponsor: VA Office of Research and Development
Enrollment: 44
Locations: 2
Primary Endpoint: The Number of Patients Who Agree to Change in Their Opioid Regimen, Including Buprenorphine Transfer
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The COVID-19 pandemic is exacerbating the challenges faced by Veterans at risk of opioid overdose including Veterans prescribed moderate-to-high dose long-term opioid therapy (LTOT) whose usual treatment resources and coping strategies may be inaccessible. This project combines established VA care components to deploy and evaluate virtual models of care for Veterans on high-risk LTOT to meet the dual challenges of maintaining social distancing and delivery high quality care.

Registry

clinicaltrials.gov

Start Date

October 1, 2020

End Date

August 12, 2021

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

VA Office of Research and Development

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Eligible participants must currently receive LTOT for chronic pain at 50 mg morphine equivalent daily dose

Exclusion Criteria

•Exclusion criteria at baseline are:
•dementia diagnosis or moderate-severe cognitive impairment
•unstable or severe untreated psychiatric disorder or medical disease that requires hospitalization
•documentation of suspected controlled substance diversion
•inability to communicate by phone

Outcomes

Primary Outcomes

The Number of Patients Who Agree to Change in Their Opioid Regimen, Including Buprenorphine Transfer

Time Frame: 30 days

Using shared decision-making with Veterans, we will based the measure on clinical reports of patient change in opioid regimen. This would be tapering (reducing opioid dose), discontinuation, or transfer to buprenorphine. Any reduction or change was considered positive for change, even if the patients returned to their initial dose. The number of patients who agree to change their opioid regimen provides a realistic indicator of overall feasibility/acceptability.